Structured evidence table for Vitamin K Bone Health Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K Bone Health Meta-Analysis | Meta-regression indicated that control sample size and bisphosphonate exposure duration in MRONJ groups were associated with effect size. | 1 | Daneshvar A (2026) | Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. |
| Vitamin K Bone Health Meta-Analysis | CONCLUSIONS: Postdiagnosis serum 25(OH)D levels appear similar in MRONJ patients and antiresorptive-exposed controls; however, the evidence is limited and of very low certainty, so conclusions should be interpreted cautiously. | 1 | Daneshvar A (2026) | Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. |
| Vitamin K Bone Health Meta-Analysis | OBJECTIVES: To compare serum 25-hydroxyvitamin D [25(OH)D] levels between patients with medication-related osteonecrosis of the jaw (MRONJ) and antiresorptive-exposed controls. | 1 | Daneshvar A (2026) | Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. |
| Vitamin K Bone Health Meta-Analysis | MATERIALS AND METHODS: Following PRISMA guidelines, PubMed, Scopus, Web of Science, and Embase were searched through September 2025 for studies including adults (≥ 18 years) treated with bisphosphonates or denosumab that reported 25(OH)D levels in MRONJ cases and exposed controls. | 1 | Daneshvar A (2026) | Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. |
| Vitamin K Bone Health Meta-Analysis | Patients with type 2 diabetes mellitus (T2DM) commonly demonstrate reduced bone quality and elevated fracture risk rates despite having normal or elevated bone mineral density (BMD). | 4 | Kashmoola IO (2026) | Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review. |
| Vitamin K Bone Health Meta-Analysis | A divergent effect on bone health was evident in patients using antidiabetic agents, with thiazolidinediones, sulfonylurea and some insulin regimens increase fracture risk. | 4 | Kashmoola IO (2026) | Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review. |
| Vitamin K Bone Health Meta-Analysis | Concerning non-antidiabetic medication used in T2DM, glucocorticoids, selective serotonin reuptake inhibitors, proton pump inhibitors and loop diuretics are among the drugs that worsen the bone architecture, causing increased fracture risk. | 4 | Kashmoola IO (2026) | Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review. |
| Vitamin K Bone Health Meta-Analysis | Beyond the pathophysiological effect of diabetes, polypharmacy has emerged as a potential, yet underappreciated contributor of skeletal fragility. | 4 | Kashmoola IO (2026) | Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review. |
Source documents